Efficacy of Bisoprolol in Reducing the Risk Chronic Obstructive Pulmonary Disorder Exacerbation
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on October 30th, 2024
|
Bisoprolol, a β1-selective β-blocker, is widely prescribed for managing hypertension, ischemic heart disease, and heart failure. Observational studies have previously suggested that the use of β1-selective β-blockers for cardiovascular conditions may be linked to a reduction in chronic obstructive pulmonary disorder (COPD) exacerbations. Consequently, a study was undertaken to investigate the potential role of bisoprolol in the management of COPD.
The clinical trial, conducted in the United Kingdom, included 1,574 participants over the age of 40 diagnosed with chronic obstructive pulmonary disease (COPD). The average baseline forced expiratory volume in the first second (FEV1) was 50%, and the mean FEV1-to-forced vital capacity (FVC) ratio was around 45%. Thirty percent of the participants were current smokers, and they had experienced an average of three exacerbation episodes in the past year. The participants were randomly assigned to receive either placebo or bisoprolol, starting at a daily dose of 1.25 mg, which could be increased to 2.5 mg, 3.75 mg, or 5 mg based on tolerance. After 52 weeks of treatment, researchers found that bisoprolol did not reduce the risk of COPD exacerbations, with both groups experiencing an average of two episodes during the study. Secondary outcomes, including changes in FEV1, the COPD Assessment Test, and the Transition Dyspnea Index, also showed no significant difference between groups. These findings are consistent with a previous study conducted in the United States, which found that metoprolol, another β1-selective β-blocker, was also ineffective in managing COPD.
The clinical trial, conducted in the United Kingdom, included 1,574 participants over the age of 40 diagnosed with chronic obstructive pulmonary disease (COPD). The average baseline forced expiratory volume in the first second (FEV1) was 50%, and the mean FEV1-to-forced vital capacity (FVC) ratio was around 45%. Thirty percent of the participants were current smokers, and they had experienced an average of three exacerbation episodes in the past year. The participants were randomly assigned to receive either placebo or bisoprolol, starting at a daily dose of 1.25 mg, which could be increased to 2.5 mg, 3.75 mg, or 5 mg based on tolerance. After 52 weeks of treatment, researchers found that bisoprolol did not reduce the risk of COPD exacerbations, with both groups experiencing an average of two episodes during the study. Secondary outcomes, including changes in FEV1, the COPD Assessment Test, and the Transition Dyspnea Index, also showed no significant difference between groups. These findings are consistent with a previous study conducted in the United States, which found that metoprolol, another β1-selective β-blocker, was also ineffective in managing COPD.